New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 8, 2012
16:02 EDTLCILannett reports Q1 EPS 10c, consensus 5c
Reports Q1 revenue $35.29M, consensus $33.76M.
News For LCI From The Last 14 Days
Check below for free stories on LCI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2014
18:38 EDTLCIOn The Fly: After Hours Movers
Subscribe for More Information
15:44 EDTLCILannett sees FY15 sales $350M-$370M, consensus $349.6M
Subscribe for More Information
15:43 EDTLCILannett reports Q4 EPS 64c, consensus 58c
Reports Q4 revenue $80.6M, consensus $79.06M.
15:27 EDTLCINotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Workday (WDAY), consensus (14c); Williams-Sonoma (WSM), consensus 53c; Bally Technologies (BYI), consensus $1.22; Guess (GES), consensus 29c; Lannett (LCI), consensus 58c; Greif (GEF), consensus 84c.
August 20, 2014
11:35 EDTLCILannett expects to launch Estradiol tablets within the next several months
Lannett Company announced that it has agreed to purchase ANDAs for Estradiol Tablets, USP, 0.5 mg, 1 mg and 2 mg, and Selegiline Hydrochloride Capsules 5 mg, upon the completion of a successful technical transfer. The company did not disclose the name of the seller nor the financial terms of the transaction. Lannett expects to launch Estradiol Tablets within the next several months and Selegiline Hydrochloride Capsules sometime thereafter. According to IMS, for the full year 2013 total sales of Estradiol Tablets, USP, 0.5 mg, 1 mg and 2 mg, and Selegiline Hydrochloride Capsules 5 mg at Average Wholesale Price were approximately $31M and $8.5M, respectively. The reference listed drug manufacturer for Estradiol Tablets is Barr Laboratories; Selegiline Hydrochloride Capsules 5 mg is the generic equivalent of Somerset Pharmaceuticals, Inc.’s Eldepryl. “We are pleased to add Estradiol Tablets and Selegiline Hydrochloride Capsules to our offering,” said Arthur Bedrosian, president and chief executive officer of Lannett. “The acquisition of these two important medications further expands and diversifies our product portfolio and complements our internal research and development efforts.”
10:08 EDTLCILannett does not expect study to significantly impact Digoxin sales
Subscribe for More Information
07:56 EDTLCILannett digoxen use in clinics unlikely to change, says Canaccord
Canaccord said the use of Lannett's digoxen drug was only prescribed to critically ill Afib patients so the mortality risk cited in a retrospective study by Turakhia is not surprising. Given the risk of thrombotic events from Afib progression far outweighing the mortality risk the firm sees little change to clinical practice. Shares of Lannett are Buy rated with a $55 price target.
August 19, 2014
12:26 EDTLCILannett downgraded to Hold from Buy at Craig-Hallum
Subscribe for More Information
09:47 EDTLCILannett could see decreased digoxin sales, says Craig-Hallum
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use